Lactoferrin compositions and methods of wound treatment

Details Lactoferrin compositions and methods of wound treatment Lactoferrin compositions and methods of wound treatment

2009-03-12

2011-10-04

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S008100, C530S350000, C530S395000, C530S400000, C424S009100, C424S085100

Reexamination Certificate

active

08030272

ABSTRACT:
The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.

REFERENCES:
patent: 4783488 (1988-11-01), Ogunbiyi et al.
patent: 4977137 (1990-12-01), Nichols
patent: 5198419 (1993-03-01), Ando et al.
patent: 5457093 (1995-10-01), Cini et al.
patent: 5561109 (1996-10-01), Mita et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571697 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5576299 (1996-11-01), Ando et al.
patent: 5766939 (1998-06-01), Conneely et al.
patent: 5834424 (1998-11-01), Valenti et al.
patent: 5849881 (1998-12-01), Conneely et al.
patent: 5955316 (1999-09-01), Conneely et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6111081 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6399570 (2002-06-01), Mann
patent: 6635447 (2003-10-01), Conneely et al.
patent: 7323443 (2008-01-01), Varadhachary et al.
patent: 7524814 (2009-04-01), Engelmayer et al.
patent: 2002/0016289 (2002-02-01), Conneely et al.
patent: 2003/0105006 (2003-06-01), Mann
patent: 2003/0190303 (2003-10-01), Kimber et al.
patent: 2004/0009895 (2004-01-01), Jung et al.
patent: 2004/0009896 (2004-01-01), Glynn et al.
patent: 2004/0082504 (2004-04-01), Varadhachary et al.
patent: 2004/0142037 (2004-07-01), Engelmayer et al.
patent: 2005/0064546 (2005-03-01), Conneely et al.
patent: 2005/0075277 (2005-04-01), Varadhachary et al.
patent: 4259467 (1992-09-01), None
patent: 6192130 (1994-07-01), None
patent: 6508641 (1994-09-01), None
patent: 6316530 (1994-11-01), None
patent: 7196529 (1995-08-01), None
patent: 07233086 (1995-09-01), None
patent: 8337526 (1996-12-01), None
patent: 10310534 (1998-11-01), None
patent: 10338632 (1998-12-01), None
patent: 11512740 (1999-11-01), None
patent: 0143722 (2001-06-01), None
patent: WO-0203910 (2002-01-01), None
patent: WO-02100445 (2002-12-01), None
patent: WO 2004/024180 (2004-03-01), None
Engelmayer et al. “Talactoferrin Stimulates Wound Healing With Modulation of Inflammation” Journal of Surgical Research, 2008.
Lyons et al. “Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study” The American Journal of Surgery 193 (2007) 49-54.
Brink, “Lactoferrin: The Bioactive Peptide that Fights Disease,”Life Extension Magazine, found at http://www.lef.org/LEFCMS/aspx/PringVersionMagic.aspx?CmsID=31812, Oct. 2000.
Legrand et al, “The N-terminal Arg2, Arg3, Arg4 of Human Lactoferrin Interact with Sulphated Molecules but Not with the Receptor Present on Jurkat Human Lymphoblastic T-Cells,” Biochem J.vol, 327, pp. 841-846 (1997).
van Berkel et al, “N-terminal Stretch Arg2, Arg3, and Arg5 of Human Lactoferrin is Essential for Binding to Heparin, Bacterial Lipopolysaccharide, Human Lysozyme and DNA,” Biochem J. vol. 328, pp. 145-151 (1997).
Yang et al, “Antitumor Activity and Specificity as a Function of Substitutions in the Lipophilic Sector of Helical Lactoferrin-derived Peptide,” Journal of Peptide Science 9, 2003, pp. 300-311.
Takayama et al, “The Bovine Lactoferrin Region Responsible for Promoting the Collagen Gel Contractile activity of Human Fibroblasts,” Biochemical and Biophysical Research Communications 299 (2002), pp. 813-817.
Yang et al., “Enhanced Antitumor Activity and Selectivity of Lactoferrin-derived peptides,” J. Peptide Res. 60, 2002, pp. 187-197.
Takayama et al, “Effects of Lactoferrin on Collagen Gel Contractile Activity and Myosin Light Chain Phosphorylation in Human Fibroblasts,” FEBS Letter 508, 2001, pp. 111-116.
Clarke et al, “Evaluation of Bovine Lactoferrin as a Topical Therapy for Chemotherapy-induced Mucositis in the Golden Syrian Hamster,” Oral Oncology 35, 1999, pp. 197-202.
Fujihara et al, “Lactoferrin Protects Against UV-B Irradiation-Induced Comeal Epithelial Damage in Rats,” Cornea 19(2); 2000, pp. 207-211.
Nakajima et al, “Lactoferrin as a Suppressor of Cell Migration of Gastrointestinal Cell Lines,” Journal of Cellular Physiology 170, 1997, pp. 101-105.
Weinberg, Eugene, “The Therapeutic Potential of Lactoferrin,” Expert Opinion Investig. Drugs, 12(5), 2003, pp. 841-851.
Cumberbatch et al, “IL-I B-induced Langerhans' cell Migration and TNF-A production in Human Skin: Regulation by Lactoferrin,” Clin Exp. Immunol 132, 2003, pp. 352-359.
He et al, “The Inhibition of Mast Cell Activation by Neutrophil Lactoferrin: Uptake by Mast Cells and Interaction with Tryptase, Chymase and Cathepsin G,” Biochemical Pharmacology 65, 2003, pp. 1007-1015.
Kimber et al, “Lactoferrin: Influence on Langerhans Cells, Epidermal Cytokines, and Cutaneous Inflammation,” Biochem Cell Biol. 80, 2002, pp. 103-107.
Ward et al, “Lactoferrin and Host Defense,” Biochem Cell Biol. 80, 2002, pp. 95-102.
Cumberbatch et al, “Regulation of Epidermal Langerhans Cell Migration by Lactoferrin,” Immunology 2000, 100, pp. 21-28.
U.S. Appl. No. 10/733,621, Agennix Incorporated.
U.S. appl. No. 10/728,521, Agennix Incorporated.
U.S. Appl. No. 10/728,275, Agennix Incorporated.
U.S. Appl. No. 10/844,865, Agennix Incorporated.
U.S. Appl. No. 10/732,429, Agennix Incorporated.
U.S. Appl. No. 10/862,213, Agennix Incorporated.
Japanese Notification of Reasons for Refusal issued Oct. 9, 2009 during prosecution of Japanese Patent Application No. 2004-536558.
Supplementary European Search Report issued May 8, 2009 during prosecution of European Patent Application No. EP 03 75 2398.
“Contemporary Traumatology,” Li Ao, editor-in-chief, People's Medical Publishing House, 1stEd., 1stPrinting, English language translation of p. 69, paragraphs 4-6; p. 70, paragraphs 2-3; p. 116; and p. 142, last paragraph to p. 143, paragraph 2, Dec. 1996.
De la Torre and Chambers, “Wound Healing, Chronic Wounds,” eMedicine Specialties> Plastic Surgery> Wound Healing; eMedicine.medscape.com; Oct. 9, 2008.
Ehrlich and Hunt, “Effects of Cortisone and Vitamin A on Wound Healing,”Annals of Surgery,167(3):324-328, 1968.
Engelmayer et al., “Talactoferrin Stimulates Wound Healing with Modulation of Inflammation,”Journal of Surgical Research, 149(2):278-286, 2008.
English language translation of Notice of Reexamination issued Jun. 9, 2010 during the prosecution of Chinese Patent Application No. 03825068.3.
Gabriel et al., “Wound Healing, Growth Factors,” eMedicine Specialties > Clinical Procedures > Soft Tissue Procedures; eMedicine.medscope.com; Feb. 17, 2006.
Mercandetti et al., “Wound Healing, Healing and Repair,” eMedicine Specialties >Plastic Surgery > Wound Healing; emedicine.medscape.com; Mar. 27, 2008.
Mulvaney and Harrington, “Cutaneous Trauma and its Treatment,”Military Dermatology; Chapter 7, pp. 143-156, 1994.
Takayama et al., “Low Density Lipoprotein Receptor-related Protein (LRP) is Required for Lactoferrin-enhanced Collagen Gel Contractile Activity of Human Fibroblasts,”The Journal of Biological Chemistry, 278(24):22112-22118, 2003.
Definition of proctitis in the medical dictionary, (2008).

Affiliated with

Also associated with

Rating

Lactoferrin compositions and methods of wound treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lactoferrin compositions and methods of wound treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin compositions and methods of wound treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4288409